<DOC>
	<DOC>NCT02220998</DOC>
	<brief_summary>The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of treatment with sofosbuvir/velpatasvir (SOF/VEL) fixed-dose combination (FDC) for 12 weeks compared to treatment with sofosbuvir (SOF) plus ribavirin (RBV) for 12 weeks in participants with chronic genotype 2 hepatitis C virus (HCV) infection.</brief_summary>
	<brief_title>Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Adults With Chronic Genotype 2 HCV Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Willing and able to provide written informed consent HCV RNA ≥ 10^4 IU/mL HCV genotype 2 Chronic HCV infection (≥ 6 months) Females of childbearing potential must have a negative serum pregnancy test Males and females of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of contraception Must be of generally good health, with the exception of chronic HCV infection, as determined by the investigator. Current or prior history of clinicallysignificant illness (other than HCV that may interfere with treatment, assessment or compliance with the protocol; Screening electrocardiogram (ECG) with clinically significant abnormalities Laboratory results outside of acceptable ranges at Screening Pregnant or nursing female or male with pregnant female partner Chronic liver disease of a nonHCV etiology (e.g., hemochromatosis, Wilson's disease, alfa1 antitrypsin deficiency, cholangitis) Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>HCV</keyword>
	<keyword>cirrhosis</keyword>
	<keyword>Sofosbuvir</keyword>
	<keyword>Sovaldi</keyword>
	<keyword>SOF/VEL</keyword>
	<keyword>GS-5816</keyword>
	<keyword>GS-7977</keyword>
	<keyword>liver</keyword>
	<keyword>Treatment naive</keyword>
	<keyword>Treatment Experience</keyword>
	<keyword>genotype 2</keyword>
</DOC>